Startup profile · funding coverage
Aktis Oncology funding, valuation and investors
Clinical-stage radiopharmaceutical biotech targeting solid tumors with alpha emitters.
Keep track of Aktis Oncology
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Series B
$175M · September 2024
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
$175M
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
public
public · Boston, Massachusetts
Investors in latest funding
Lead: RA Capital Management
Other: RTW Investments
Latest tracked event: IPO (January 2026). It is shown separately because it is not counted as disclosed equity funding.
Overview
Aktis Oncology develops targeted alpha radiopharmaceuticals for solid tumors using miniprotein radioconjugates designed to deliver potent radiation selectively to cancer cells. Incubated at MPM Capital, the company advanced clinical programs before pricing an upsized IPO on Nasdaq (AKTS) in January 2026 with approximately $318M gross proceeds per investor relations. Aktis raised a $175M Series B in September 2024 led by RA Capital with RTW and Janus Henderson participating. Andreessen Horowitz appears on the investor list.
Why Aktis Oncology is interesting
Miniprotein radioconjugates for cancers underserved by existing radiopharma — MPM-incubated, IPO'd Nasdaq (AKTS) January 2026 with ~$318M gross proceeds.
Product & use cases
Aktis engineers miniprotein carriers bound to alpha-emitting isotopes — delivering high-energy short-range radiation to tumor cells while limiting damage to surrounding healthy tissue compared to some beta therapies.
- Solid tumor oncology patients eligible for targeted radiopharmaceutical trials
- Biopharma partnerships on radioconjugate platform expansion
- Investors seeking clinical-stage radiopharma exposure via AKTS
Key facts
- IPO (Jan 2026): upsized Nasdaq AKTS; ~$318M gross proceeds — Aktis IR
- Series B (Sep 2024): $175M led by RA Capital — PR Newswire
- Miniprotein alpha radiopharmaceuticals for solid tumors
Funding history (newest first)
IPO
2026-01 ~$318M gross- Public markets
Series B
2024-09 $175M- RA Capital Management (lead)
- RTW Investments (participant)
Source: https://www.prnewswire.com/news-releases/aktis-series-b
Investors in our directory
Funds linked from Aktis Oncology's profile — open a fund page for stage focus and related deal articles.
Competitive landscape
Edge: Alpha emitter physics (short path length) suits solid tumor penetration challenges; miniprotein scaffold differentiated from antibody-based radiopharmaceuticals like Pluvicto-class agents.
Radiopharmaceuticals are hot after Pluvicto success — Aktis IPO'd into receptive public markets January 2026. Clinical readouts determine value; RA Capital-led B-round signals specialist biotech conviction. a16z exposure tracks portfolio biotech winners.
-
Novartis (Pluvicto/Lutathera) incumbent
Approved radiopharmaceuticals; Aktis clinical-stage challenger on solid tumors.
-
Lantheus / radiopharma peers direct
Competing clinical programs in targeted radiation oncology.
-
Fusion Pharmaceuticals (AstraZeneca) direct
Radioconjugate M&A benchmark; Aktis independent IPO path.
Notable stories
- Aktis emerged from MPM Capital incubation before scaling to one of the larger biotech IPOs of early 2026 (investor relations).
Industries
Market / IPO context
Ticker: AKTS (NASDAQ)
IPO status: public
IPO date: 2026-01
Editorial / static context — not a live quote.
Related funding articles
Venture Capital Tracker pieces that cover Aktis Oncology's financing or category context.
FAQs about Aktis Oncology
Practical answers founders, operators, and investors typically search for.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.